Intranasal substituted cathinone "bath salts" psychosis potentially exacerbated by diphenhydramine

Journal of Addiction Medicine

Volumn 7, Issue 3, 2013, Pages 163-168

  Gunderson, Erik W ^a,b,c   Kirkpatrick, Matthew G ^d   Willing, Laura M ^e   Holstege, Christopher P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Center for Wellness and Change   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

3,4 methylenedioxypyrovalerone; Bath salts; Designer drug; Diphenhydramine; Mephe drone; Psychosis

Indexed keywords

CATHINONE; DIPHENHYDRAMINE; DULOXETINE; ALKALOID; CENTRAL STIMULANT AGENT; DESIGNER DRUG; HYPNOTIC SEDATIVE AGENT; INORGANIC SALT;

ADULT; ARTICLE; CASE REPORT; CLINICAL EVALUATION; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY CARE; FOLLOW UP; HUMAN; INSOMNIA; IRRITABILITY; LOW BACK PAIN; MALE; MALE SEXUAL DYSFUNCTION; MENTAL HEALTH; MOTIVATION; PARANOIA; PATIENT COUNSELING; PATIENT SAFETY; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SUBSTANCE ABUSE; SUICIDAL IDEATION; VISUAL HALLUCINATION; WEIGHT REDUCTION; ADDICTION; BATH; CLASSIFICATION; DRUG INTERACTION; EMERGENCY TREATMENT; INTRANASAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PACKAGING; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ALKALOIDS; BATHS; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; DIPHENHYDRAMINE; DRUG INTERACTIONS; EMERGENCY TREATMENT; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PRODUCT LABELING; PSYCHOSES, SUBSTANCE-INDUCED; SALTS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84880990709     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31829084d5     Document Type: Article

References (20)

1. Brahm NC, Yeager LL, Fox MD, et al. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm 2010;67(16):1344-1350.
2. Brandt SD, Sumnall HR, Measham F, et al. Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal 2010;2(8):377-382.
3. Centers for Disease Control and Prevention. Emergency department visits after use of a drug sold as "bath salts"-Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep 2011;60(19):624-627.
4. Drug Enforcement Agency: Office of Diversion Control; Drug and Chemical Evaluation Section. Background, Data and Analysis of Synthetic Cathinones: Mephedrone (4-MMC), Methylone (MDMC) and 3, 4-Methylenedioxypyrovalerone (MDPV). Washington D. C.: Drug Enforcement Agency: Office of Diversion Control; Drug and Chemical Evaluation Section, 2011.
5. Gunderson EW, Haughey HM, Ait-Daoud N, et al. "Spice" and "K2" herbal highs: a case series and review illustrating the pharmacological and biopsychosocial implications of synthetic cannabinoid use. Am J Addict 2012;21(4):320-326.
6. Hatsukami DK, Fischman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA 1996;276(19):1580-1588.
7. Kirkpatrick MG, Gunderson EW, Johanson CE, et al. Comparisonofintranasal methamphetamine and D-amphetamine self-administration by humans. Addiction 2012a; 107(4):783-791.
8. Kirkpatrick MG, Gunderson EW, Perez AY, et al. A direct comparison of the behavioral and physiological effects of methamphetamine and 3, 4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2012b;219(1):109-122.
9. Kriikku P, Wilhelm L, Schwarz O, et al. New designer drug of abuse: 3, 4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci Int 2011;210(1-3):195-200.
10. Lawrence DT, Bechtel L, Walsh JP, et al. The evaluation and management of acute poisoning emergencies. Minerva Med 2007;98(5):543-568.
11. Ojanpera IA, Heikman PK, Rasanen IJ. Urine analysis of 3, 4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther Drug Monit 2011;33(2):257-263.
12. Penders TM, Gestring R. Hallucinatory delirium following use of MDPV: "bath salts." Gen Hosp Psychiatry 2011;33(5):525-526.
13. Ross EA, Watson M, Goldberger B. "Bath salts" intoxication. N Engl J Med 2011;365(10):967-968.
14. Shaham Y, Shalev U, Lu L, et al. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 2003;168(1-2):3-20.
15. Spiller HA, Ryan ML, Weston RG, et al. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol (Phila) 2011;49(6):499-505.
16. Striebel JM, Pierre JM. Acute psychotic sequelae of "bath salts." Schizophr Res 2011;133(1-3):259-260.
17. Substance Abuse and Mental Health Services Administration. Treatment of Stimulant Use Disorders. Treatment Improvement Protocol (TIP) Series, No. 33. Rockville, MD: Center for Substance Abuse Treatment, 2009.
18. Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 2007;64(11):1575-1579.
19. Winstock AR, Mitcheson LR, Deluca P, et al. Mephedrone, new kid for the chop? Addiction 2011a; 106(1):154-161.
20. Winstock AR, Mitcheson LR, Ramsey J, et al. Mephedrone: use, subjective effects and health risks. Addiction 2011b; 106(11):1991-1996.